

VMC Ambulatory Pharmacy and Therapeutics Updates

September 2024 Decisions and Highlights

Medication Name or Topic Discussed	Decision Point / Discussion	Comments and Go-Live Date
VACCINATIONS FOR PATIENTS WITH MEDICARE	Follow-up from previous meeting re: lack of reimbursement for vaccinations in patients with Medicare other than: flu, pneumococcal, COVID, and hepatitis B. Shingrix, tetanus (Td and Tdap) are commonly given to patients in the clinic network 65+ with Medicare. Recommendation approved to no longer offer vaccinations for Shingrix to patients with Medicare in Clinic Network and to refer to retail pharmacies to utilize Medicare Part D benefits. EPIC alert to be created to assist providers in avoiding ordering for patients in clinic who meet these conditions.	Education provided at Sept provider meeting. EPIC alert go-live TBD (likely Oct 2024)
NIRSEVIMAB (BEYFORTUS®)	APPROVED addition of nirsevimab (BEYFORTUS®) to clinic formulary via the Vaccines For Children (VFC) program and to offer to eligible patients.	Go-live late Sept 2024
ADULT RSV VACCINE REVIEW	Reviewed adult RSV vaccines (Arexvy®, Abrysvo®, and mResvia®) and decision made to NOT offer adult RSV vaccines this year. Patients should be referred to retail pharmacies for vaccination.	N/A
MENINGOCOCCAL VACCINE REVIEW FOR PEDIATRICS	Reviewed meningococcal vaccines, specifically with new FDA approval for Penbraya® - a pentavalent vaccine. Decision made to NOT recommend adding Penbraya® to VFC formulary list and continue to utilize current vaccines.	N/A
SSRI/SNRI MEDICATION GUIDE FOR PRESCRIBERS	Informational handout reviewed and approved for addition to Depression Clinical Pathway Guideline (CPG).	N/A

For questions or more information, please contact Kamal Sandhu, PharmD – Clinical Pharmacy Manager and P&T Co-Chair
kamal_sandhu@valleymed.org